Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, will participate in the European Association of Nuclear Medicine (EANM) Congress 2024 in Hamburg, from October 19-23. At this year’s congress, research findings on Akiram’s drug candidate AKIR001, resulting from several successful academic collaborations, will be presented. Akiram Therapeutics has developed 177Lu-AKIR001, a new type…
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, has entered into an agreement with a leading Swedish university hospital for the manufacturing of 177Lu-AKIR001, a radiopharmaceutical designed for treating patients with solid tumors. This agreement marks an important step towards the Phase I first-in-human study, which is planned to start in 2024. Akiram…
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, is pleased to announce the addition of Anna Törner and Peder Walberg to its board of directors. Their combined expertise in drug development and regulatory affairs fortifies the company’s position as it advances toward the planned clinical trials of an innovative cancer treatment in 2024….
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, is pleased to announce that the company’s founder, Professor Marika Nestor and her research group at Uppsala University have been granted SEK 6 million by the Erling-Persson Foundation. This funding will advance a groundbreaking research project aimed at developing novel radiopharmaceuticals for the treatment of…
Akiram Therapeutics, a Swedish biotech company specializing in radiotherapy will present promising preclinical data at the European Association of Nuclear Medicine (EANM) Congress taking place in Vienna, Austria on September 9–13. The data showcases the potential of the company’s radiopharmaceutical 177Lu-AKIR001 targeting tumor lesions for therapeutic purposes. A Phase 1 study is planned for 2024….
The Swedish radioimmunotherapy company Akiram Therapeutics, developing targeted cancer therapy, has raised SEK 68 million in a share issue led by Sciety and the network Sciety Venture Partners. The investment company Linc AB participated in the share issue with SEK 20 million. The proceeds from the financing will be used for GMP production of the…